HALOPERIDOL DECANOATE IN CHRONIC-SCHIZOPHRENIA - A STUDY OF 12 MONTHS WITH PLASMA-LEVELS

被引：13

作者：

ALTAMURA, CA ^{[1
]}

COLACURCIO, F ^{[1
]}

MAURI, MC ^{[1
]}

MORO, AR ^{[1
]}

DENOVELLIS, F ^{[1
]}

机构：

[1] UNIV MILAN,DEPT CLIN PSYCHIAT,CLIN NEUROPSYCHOPHARMACOL LAB,I-20122 MILAN,ITALY

来源：

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | 1990年 / 14卷 / 01期

关键词：

C; catatonic; D; DG; diagnosis; disorganized; EPSE; extrapyramidal side-effects rating scale; haioperidol decanoate; haloperidol; haloperidol decanoate; HL; HL-D; L/D; level/dose ratio; not performed; NP; P; paranoid; patient; pharmacokinetics; PL; plasma levels; PT; schizophrenia; SD; standard deviation; U; undifferentiated; years; yrs;

D O I：

10.1016/0278-5846(90)90061-K

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

1. 1. Clinical activity, extrapyramidal side-effects were evaluated in 22 schizophrenic out patients diagnosed according to DSM III and treated with haioperidol decanoate (50-300 mg i.m. monthly dose) for 12 months. 2. 2. BPRS total scores did not show significant fluctuations showing a clinical stability of the patient population. 3. 3. Patients with a duration of illness > 10 yrs (Group 2) showed significant (p < 0.01) higher EPSE total scores compared to those with a duration of illness < 10 yrs (Group 1). 4. 4. A positive correlation was found between the administered dose and haloperidol plasma levels. 5. 5. Patients from Group 2 reached the steady-state more slowly and showed a lower total L/D ratio compared to those from Group 1. 6. 6. The pharmacokinetic approach seems desirable in order to adjust the dose and avoid schizophrenic relapses. © 1990.

引用

页码：25 / 35

页数：11

共 21 条

[11]

OVERALL JE, 1962, PSYCHOL REP, V10, P799

[12]

PARENT M, 1981, Acta Psychiatrica Belgica, V81, P399

[13]

POTKIN SG, 1985, PSYCHOPHARMACOL BULL, V21, P59

[14] PHARMACOKINETICS OF HALOPERIDOL DECANOATE - A 2-YEAR FOLLOW-UP [J].

REYNTJENS, AJM ;

HEYKANTS, JJP ;

WOESTENBORGHS, RJH ;

GELDERS, YG ;

AERTS, TJL .

INTERNATIONAL PHARMACOPSYCHIATRY, 1982, 17 (04) :238-246

[15]

SIMPSON RM, 1979, ACTA PSYCHIATR SCA S, V212, P11

[16]

SMITH RC, 1985, PSYCHOPHARMACOL BULL, V21, P52

[17]

VANPUTTEN T, 1984, ARCH GEN PSYCHIAT, V41, P1036

[18]

VANPUTTEN T, 1988, PSYCHOPHARMACOL BULL, V24, P172

[19] TOLERANCE AND SERUM LEVELS OF HALOPERIDOL DURING PARENTERAL AND ORAL HALOPERIDOL TREATMENT IN GERIATRIC-PATIENTS [J].

VIUKARI, M ;

SALO, H ;

LAMMINSIVU, U ;

GORDIN, A .

ACTA PSYCHIATRICA SCANDINAVICA, 1982, 65 (04) :301-308

[20]

YOUSSEF HA, 1983, ACTA THERAP, V9, P215

← 1 2 3 →